

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Thor	Confirmation No.:	8365
Appl No.:	10/799,490	Group Art Unit:	1614
Filed:	March 12, 2004	Examiner:	Jiang, Shaojia A.
For:	METHODS OF USING COMPOUNDS WITH COMBINED 5-HT1A ANTAGONIST AND SSRI ACTIVITIES AS-NEEDED TO TREAT SEXUAL DYSFUNCTION (AS AMENDED)		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION REQUIREMENT**

This is in response to the Office Action dated April 20, 2007. Applicant hereby provisionally elects with traverse to prosecute the claims of Group I (Claims 1-21) and expressly reserves the right to file divisional applications or take such other appropriate measures deemed necessary to protect the inventions in the remaining claims.

In addition, within Group I Applicant provisionally elects with traverse to prosecute the species of active agent that corresponds to claim 1(a). Applicant respectfully traverses as to subsections (a) and (b) of claim 1, since the compound of claim 1(b) is encompassed by claim 1(a). Applicant respectfully submits that species 1(a) and 1(b) should be examined together.

Further, within Group I Applicant also elects without traverse: 1) the additional active agent corresponding to the second listed compound of claim 20; 2) the mode of administration "oral" within claims 10, 13, and 14); and 3) the unit dosage form according to claim 7.

It is understood that upon allowance of a generic claim, Applicant will be entitled to consideration of claims to additional species that are written in dependent form or otherwise include all the limitations of an allowed generic claims as provided by 37 C.F.R. §1.141. Currently, claims 1, 3-12, 15, and 19-20 within Group I are generic.

Should the Examiner have further questions or comments with respect to examination of this case, it is respectfully requested that the Examiner telephone the undersigned so that further examination of this application can be expedited.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those, which may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required

Appl No.: 10/799,490  
Response Dated May 17, 2007  
Reply to Restriction Requirement of April 20, 2007

therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,

/edward r. ergenzinger/

Edward R. Ergenzinger  
Registration No. 47,549

**CUSTOMER NO. 00826**  
**ALSTON & BIRD LLP**  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Raleigh Office (919) 862-2200  
Fax Raleigh Office (919) 862-2260

ELECTRONICALLY FILED USING THE EFS-WEB ELECTRONIC FILING SYSTEM OF THE UNITED STATES PATENT & TRADEMARK OFFICE ON May 17, 2006.